Trizivir

 

Generical name: abacavir, zidovudine, and lamivudine

Brand name: Trizivir
Drug class: Antiviral combinations

What is Trizivir?

Trizivir
Trizivir

Trizivir is a mixture that consists of Abacavir, lamivudine as well as zidovudine. Abacavir as well as lamivudine and zidovudine are antiviral medicines which prevent the human immunodeficiency virus (HIV) from multiplying within your body.

Trizivir serves to combat HIV, a virus that causes acquired immune deficiency syndrome (AIDS). This medication is not an effective treatment for HIV and AIDS.

Trizivir is used by itself or in conjunction with other antiviral drugs.

Warnings and precautions

Hypersensitivity Reactions

Hypersensitivity that is fatal and often severe reactions have been observed when abacavir is a component of the TRIZIVIR. The hypersensitivity reactions have included anaphylaxis, multi-organ failure and usually occurred within the first six weeks following treatment with Abacavir (median time to the onset of 9 days) however, abacavir hypersensitivity reactions can occur throughout treatment.

Patients with the HLA-B*5701 allele have a greater chance of experiencing hypersensitivity reactions to abacavir however, those who do not have the HLA-B*5701 allele are not at risk of developing hypersensitivity reactions. Hypersensitivity towards abacavir was found in around 206 (8%) of the 2,670 patients who participated in 9 clinical studies using Abacavir-containing drugs where HLA-B*5701 testing was not conducted.

The frequency of hypersensitivity reactions to abacavir suspected in clinical trials was 1 % when patients carrying the HLA B*5701 allele were ruled out. For any patient being receiving abacavir treatment, the medical diagnosis of hypersensitivity reaction remains the primary basis for the clinical decision-making process.

Due to the possibility of serious, severe hypersensitivity, possibly fatal reactions to abacavir

 

Hematologic Toxicity/Bone Marrow Suppression

Zidovudine, which is a component of TRIZIVIR has been linked with hematologic toxicities, such as anemia and neutropenia, specifically in patients suffering from an advanced form of HIV-1. TRIZIVIR should be treated with caution for patients suffering from bone marrow dysfunction as evidenced by a granulocyte count of less than 1000 cells/millimetre or hemoglobin lower than 9.5 grams/dL.

A regular blood count is strongly advised for patients suffering from advanced HIV-1 disease treated with the TRIZIVIR. Regular blood counts are recommended for all HIV-1 patients. If neutropenia or anemia develops the need for a dose interruption is required.

Leave a Reply